These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37004887)

  • 61. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative effectiveness of infliximab and adalimumab for Crohn's disease.
    Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger C; Chen L; Xie F; Curtis JR; Lewis JD
    Clin Gastroenterol Hepatol; 2014 May; 12(5):811-817.e3. PubMed ID: 23811254
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL
    Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
    Buttgereit F; Aelion J; Rojkovich B; Zubrzycka-Sienkiewicz A; Chen S; Yang Y; Arikan D; D'Cunha R; Pang Y; Kupper H; Radstake T; Amital H
    Arthritis Rheumatol; 2023 Jun; 75(6):879-889. PubMed ID: 36512671
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study.
    Jung YS; Han M; Park S; Cheon JH
    Korean J Intern Med; 2020 Sep; 35(5):1104-1113. PubMed ID: 32306709
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
    Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
    Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.
    Lian F; Zhou J; Wei C; Wang Y; Xu H; Liang L; Yang X
    Clin Rheumatol; 2015 Nov; 34(11):1913-20. PubMed ID: 26070537
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
    Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis.
    Spoendlin J; Desai RJ; Franklin JM; Glynn RJ; Payne E; Schneeweiss S
    Clin Pharmacol Ther; 2020 Oct; 108(4):874-884. PubMed ID: 32320482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.